Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis

Several treatments are currently available for relapsing-remitting multiple sclerosis. Among them, interferon (IFN) beta remains a valid treatment approach because of its good benefit/risk profile. Due to the need for frequent administration (weekly, at a minimum), the use of IFN beta is limited by...

Descripción completa

Detalles Bibliográficos
Autores principales: Cocco, Eleonora, Marrosu, Maria Giovanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4431469/
https://www.ncbi.nlm.nih.gov/pubmed/26056458
http://dx.doi.org/10.2147/TCRM.S69123

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4431469/
https://www.ncbi.nlm.nih.gov/pubmed/26056458
http://dx.doi.org/10.2147/TCRM.S69123

Ejemplares similares